Literature DB >> 21512861

Single nucleotide polymorphisms and haplotypes of MMP-14 are associated with the risk and pathological development of oral cancer.

Chia-Jui Weng1, Mu-Kuan Chen, Chiao-Wen Lin, Tsung-Te Chung, Shun-Fa Yang.   

Abstract

BACKGROUND: Matrix metalloproteinase (MMP)-14 is one of the pericellular collagenases to degrade extracellular matrix (ECM), which is involved to the modulation of susceptibility or clinicopathological features of a cancer. The contributions of MMP-14 on the susceptibility or clinicopathological features of certain cancers have been well documented, and the expression of MMP-14 in oral squamous cell carcinoma (OSCC) also has been observed. This study was designed to examine the association of MMP-14 gene polymorphisms with the susceptibility and clinicopathological development of OSCC.
METHODS: A total of 363 patients with OSCC and 506 healthy control subjects were recruited. Six single nucleotide polymorphisms (SNPs) of MMP-14 genes were analyzed by polymerase chain reaction-restriction fragment length polymorphism genotyping and haplotype-base analysis.
RESULTS: MMP-14 +7096 TC/CC genotypes might lower the risk of OSCC, and MMP-14 +6767 GA/AA genotypes cause a poor clinical status in OSCC patients. The +6727 C: +6767 G: +7096 T: +8153 G haplotype and diplotype increased the risk for OSCC by 1.706-fold (95% confidence interval (CI) 1.383-2.105) and 2.276-fold (95% CI = 1.531-3.384), respectively, compared with the reference. The diplotype with at least one CGTG exhibited a high risk (adjusted odds ratio, 1.639; 95% CI, 1.005-2.673) for developing a poor clinicopathological diagnosis of OSCC compared with the others/other diplotype.
CONCLUSIONS: The +7096 and +6767 polymorphic genotypes and haplotype +6727 C: +6767 G: +7096 T: +8153 G of MMP-14 gene might contribute to the prediction of susceptibility and pathological development of OSCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512861     DOI: 10.1245/s10434-011-1736-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  A role of MMP-14 in the regulation of invasiveness of nasopharyngeal carcinoma.

Authors:  Jian Zhao; Zhongyu Kong; Feng Xu; Wei Shen
Journal:  Tumour Biol       Date:  2015-06-04

2.  Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer.

Authors:  Eugene K Lee; Yuanquing Ye; Ashish M Kamat; Xifeng Wu
Journal:  Cancer       Date:  2013-03-25       Impact factor: 6.860

Review 3.  Genotypic distribution of single nucleotide polymorphisms in oral cancer: global scene.

Authors:  Shaleen Multani; Dhananjaya Saranath
Journal:  Tumour Biol       Date:  2016-09-20

4.  Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma.

Authors:  Liang Wang; Jun Yuan; Yanyang Tu; Xinggang Mao; Shiming He; Guoqiang Fu; Jianhai Zong; Yongsheng Zhang
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

Review 5.  Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review.

Authors:  Edyta Wieczorek; Ewa Jablonska; Wojciech Wasowicz; Edyta Reszka
Journal:  Tumour Biol       Date:  2014-10-29

6.  Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation.

Authors:  Chia-Ming Yeh; Chiao-Wen Lin; Jia-Sin Yang; Wei-En Yang; Shih-Chi Su; Shun-Fa Yang
Journal:  Oncotarget       Date:  2016-04-19

7.  Gene Polymorphism of MUC15, MMP14, BRAF, and COL1A1 Is Associated with Capsule Formation in Hepatocellular Carcinoma.

Authors:  Wei Sun; Yongchao Zhang; Bozhi Liu; Youjia Duan; Wei Li; Jinglong Chen
Journal:  Can J Gastroenterol Hepatol       Date:  2021-04-28

8.  Genetic association of MMP14 promoter variants and their functional significance in gallbladder cancer pathogenesis.

Authors:  Vinay J; Debakanta Mishra; Dinesh Meher; Sashibhusan Dash; Kusumbati Besra; Niharika Pattnaik; Shivaram Prasad Singh; Manjusha Dixit
Journal:  J Hum Genet       Date:  2021-03-16       Impact factor: 3.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.